Get started
EDWARDS LIFEDRNEDWARDS LIFEDRNEDWARDS LIFEDRN

EDWARDS LIFEDRN

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

E1WL34 trade ideas

Cup and HandleEW got caught in a bearish Rising wedge, pulled back and appears to have recovered Handle low changed though due to pull back from RW NV is high R will most likely be a prior high of 87.79 before it fell from RW pattern This stock split a while back and is a long term uptrend Not a recommendation Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral valve diseases, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
NYSE:EWLong
by lauralea
Cup and HandleThis stock split a while back and shares went down post split. Was over 200 when split occurred. I am wondering if same will happen when TSLA splits? Just a tought EW appears to be at hard R right now . I am watching. Not a recommendation. Monthly candle looks good. NV high Short is low. No rising wedges noted Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral valve diseases, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
NYSE:EWLong
by lauralea
Edwards Lifesciences Corp. Bullish Upgrade Citi analyst Joanne Wuensch initiated coverage of Edwards Lifesciences with a Buy rating and $252 price target. The analyst said the focus of the company is on their TAVR and TMTT franchises -- which she called large, growing market opportunities -- noting that the TAVR market is expected to increase to reach $7B in 2024 from $4B today and the TMTT market expected to reach $3B in 2024 from $1B estimated in 2021. thefly.com Average analysts price target $262 | Overweight Company profile Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
NYSE:EWLong
by RedHotStocks
EWSystem T Performances: Annual Compound Profit 40%, Win Rate 55%, Risk/Reward Ratio 1:2, 20 Years of Backtesting Data, Over 100 Markets. * Click Like and Follow to Support My Work! --- Hi Traders, I'd like to introduce the System T, a computerized trading system that analyzed and backtested the 20 years history data of over 100 markets. This post is my sharing of how I think about systematic trading and the signals generated by the System T. (This is my opinion only, NOT the financial advice.) I think that for the system to open a trade and manage risk, it only needs a buy signal & a stop-loss signal clearly on the chart. Once the system finds a good trend, it will ride it as long as possible. The stop-loss will be adjusted accordingly to the new price movement. (Remember to follow this trade idea and follow my profile to get updates about the stop-loss adjustment and sell signal based on the latest price and market conditions daily.) System T performances above will give you an idea of how it performs in the last 20 years. Notice that this result was achieved only if I strictly followed the rule: "Only and Always Buy & Sell based on the System Signals". Don't sell when there is no sell signal as we all want to follow the good trends til the end like everything in life does. \(^-^)/ Also, my system is extremely diversified through over 100 markets so that it only risks less than -1% of the total capital per trade. Thank you and good luck! --- DISCLAIMER: I am NOT a financial advisor, and nothing I say is meant to be a recommendation to buy or sell any financial instrument. My views are general in nature and I am not giving financial advice. You should not take my opinion as financial advice. This is my opinion only. Do your own due diligence, and take 100% responsibility for your financial decisions. Trading and investing are risky! Don't invest money you can't afford to lose, because many traders and investors lose money. There are no guarantees or certainties in trading. - Content is for education purposes only, not investment advice. - Trading involves a high degree of risk. - We’re not investment or trading advisers. - Nothing we say is a recommendation to buy or sell anything. - There are no guarantees or certainties in trading. - Many traders lose money. Don’t trade with money you can’t afford to lose.
NYSE:EWLong
by System_T
ED, Edward Lifescences Corp. - Trailing Stop, RR, %ProfitabilityNYSE:EW Does the technical analysis work? Look at this! The important thing is to let the profits run and quickly cut the losses when the trend turns against you. How would your account behave after 100 trades if 6/10 make a loss and 4/10 make a profit? The answer in the Risk Reward is how much you earn when the trade makes a profit, and that's where the difference is made, i.e. compensating for all losses and creating profits on the long run. In addition to this, you must also decide on risk management so that your maximum exposure is appropriate for your risk profile, and does not result in heavy drawdowns to suffer and possibly irrecoverable.
NYSE:EWLong
by SwissTradingSchool
1
Edwards Lifescience is a long into earnings . While Pharmaceutical and Biopharma stocks have been taking a beating in 2018/19 medical device makers are on a roll , they are in one of the hottest trends in the market, seemingly bullet proof from they bears. NYSE:EW is on a perfect trend for 2 years and as earnings approach on the 23rd July it looks like a real good bet to move higher. Indicators are all setting up bullish just at the right time. Stock is poised to make a nearterm breakout. News related selling has subsided and they buyers have flocked back in. AVERAGE ANALYSTS PRICE TARGET $199 AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT P/E RATIO 55 SHORT INTEREST 1.8% COMPANY PROFILE Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Critical Care portfolio products hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA..
NYSE:EWLong
by RedHotStocks